One major direction is broadening the mutation profiles targeted by these assays to include genetic alterations specific to a variety of cancer types, such as KRAS mutations for pancreatic and colorectal cancers or PIK3CA mutations for breast cancer. This evidence concerns the gene KRAS and breast cancer.